Galectin-9 Acts as a Prognostic Factor with Antimetastatic Potential in Hepatocellular Carcinoma |
Zhang, Zhao-Yang
(Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University)
Dong, Jia-Hong (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Chen, Yong-Wei (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Wang, Xian-Qiang (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Li, Chong-Hui (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Wang, Jian (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Wang, Guo-Qiang (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Li, Hai-Lin (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) Wang, Xue-Dong (Department of Hepatobiliary Surgery, Division of Surgery, Chinese PLA General Hospital) |
1 | Matsushita N, Nishi N, Seki M, et al (2000). Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem, 275, 8355-60. DOI |
2 | Miles FL, Pruitt FL, van-Golen KL, et al (2008). Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis, 25, 305-24. DOI |
3 | Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. DOI ScienceOn |
4 | Pasco S, Ramont L, Maquart FX, et al (2004). Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol, 49, 221-33. DOI |
5 | Qicheng Zhao, Xiuli Guo, Gerard B Nash, et al (2009). Circulating Galectin-3 Promotes Metastasis by Modifying MUC1 Localization on Cancer Cell Surface. Cancer Res, 69, 6799-806. DOI |
6 | Saita N, Goto E, Yamamoto T, et al (2002). Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol, 128, 42-50. DOI |
7 | Tsuchiyama Y, Wada J, Zhang H (2000). Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int, 58, 1941-52. DOI |
8 |
Wada J, Ota K, Kumar A, et al (1997). Developmental regulation, expression, and apoptotic potential of galectin-9, a |
9 | Wiersma VR, de Bruyn M, Helfrich W, et al (2011). Therapeutic potential of Galectin-9 in human disease. Med Res Rev, doi: 10.1002/med. 20249. |
10 | Zhang ZY, Xu KS, Wang JS, et al (2008). Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R Coll Radiol), 20, 61-6. DOI |
11 |
Asakura H, Kashio Y, Nakamura K, et al (2002). Selective eosinophil adhesion to fibroblast via IFN- |
12 | Atsuya N, Keiko N, Souichi O, et al (2008). Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology, 18, 735-44. DOI |
13 | Engbring JA, Kleinman HK (2003). The basement membrane matrix in malignancy. J Pathol, 200, 465-70. DOI |
14 | Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87. DOI ScienceOn |
15 | Gray CA, Adelson DL, Bazer FW, et al (2004). Discovery and characterization of an epithelial-specific galectin in the endometrium that forms crystals in the trophectoderm. Proc Natl Acad Sci USA, 101, 7982-7. DOI |
16 | Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70. DOI ScienceOn |
17 | Hann HW, Lee J, Bussard A, et al (2004). Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res, 64, 7329-35. DOI |
18 | Hirashima M, Kashio Y, Nishi N, et al (2004). Galectin-9 in physiological and pathological conditions. Glycoconj J, 19, 593-600. |
19 | Hsu DK, Liu FT (2004). Regulation of cellular homeostasis by galectins. Glycoconj J, 19, 507-15. |
20 | Zou W (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 5, 263-74. DOI ScienceOn |
21 | Hughes RC (2001). Galectins as modulators of cell adhesion. Biochimie, 83, 667-76. DOI |
22 | Irie A, Yamauchi A, Kontani K, et al (2005). Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res, 11, 2962-8. DOI |
23 | Kageshita T, Kashio Y, Yamauchi A, et al (2002). Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer, 99, 809-16. DOI |
24 | Keiko N, Tomohiro A, Souichi O, et al (2008). Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions. J Immunol, 181, 7660-9. DOI |
25 | Kilpatrick DC (2002). Animal lectins: A historical introduction and overview. Biochim Biophys Acta, 1572, 187-97. DOI ScienceOn |
26 | Kim R, Emi M, Tanabe K, et al (2006). Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res, 66, 5527-36. DOI |
27 | Kobayashi T, Kuroda J, Ashibara E, et al (2010). Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia, 24, 843-50. DOI |
28 | Li N, Lucy W, Herbert C, et al (2009). Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res, 1, 358-66. |
29 | Matsumoto R, Hirashima M, Kita H, et al (2002). Biological activities of ecalectin: a novel eosinophil-activating factor. J Immunol, 168, 1961-67. DOI |
30 | Matsumoto R, Matsumoto H, Seki M, et al (1998). Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem, 273, 16976-84. DOI |
![]() |